ArticleCancer research communications2026
Multiplexed P21/MCM-2 Detection Predicts Relapse and May Identify Tyrosine Kinase Inhibitor-Resistant Patients in Clear Cell Renal Cell Carcinoma.
Article in Cancer research communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Current clinical tools for predicting relapse and guiding adjuvant therapy in clear cell renal cell carcinoma (ccRCC) lack precision, especially in intermediate-risk disease. This study evaluated whether a nonproliferative tumor cell phenotype, P21 (CDKN1A inhibitor)-positive and MCM2 (DNA replication protein)-negative (P21+/MCM2-), could serve as a robust biomarker to improve prognostic stratification and guide postnephrectomy treatment decisions. We used multiplex immunofluorescence and Artificial Intelligence-based image analysis on nephrectomy specimens from three independent ccRCC cohorts: UK arm of the SORCE trial (n = 382), Korean (n = 71), and Scottish (n = 88). An optimal 2% cutoff for P21+/MCM2- cells was determined using X-tile software. Additional analyses assessed endoglin/CD105 coexpression, paired primary-metastatic samples (n = 41), and associations with adjuvant sorafenib therapy. In two intermediate-risk ccRCC cohorts (SORCE, n = 63; Korean, n = 71), patients with >2% P21+/MCM2- cells had significantly longer time to relapse [HR = 0.17; 95% confidence interval (CI), 0.06-0.54; HR = 0.27; 95% CI, 0.10-0.72]. Prognostic value was confirmed in high-risk (SORCE, HR = 0.43; 95% CI, 0.19-0.99) and all-risk (Scottish, HR = 0.37; 95% CI, 0.14-0.98) cohorts. Notably, patients with high P21+/MCM2- levels on placebo fared better than those receiving adjuvant TKI therapy (HR = 0.29; 95% CI, 0.16-0.50). In 41 paired samples, 85% showed higher P21+/MCM2- abundance in metastases than in primary tumors. As a conclusion, P21+/MCM2- cell count is a robust biomarker that refines relapse risk stratification in ccRCC and identifies patients who may not benefit from adjuvant tyrosine kinase inhibitor (TKI) therapy. High levels of these nonproliferative, senescent-like cells suggest tumor dormancy and a more favorable outcome without treatment. SIGNIFICANCE: After surgery for clear cell renal cell carcinoma, relapse risk and benefit from adjuvant therapy remain uncertain. We identify a distinct P21+/MCM2- tumor phenotype, nonproliferative and senescent-like, linked to favorable outcomes. Across three cohorts, >2% of these cells reduced relapse risk, but benefit was lost with adjuvant TKIs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.